DLK1/DIO3 locus upregulation by a β-catenin-dependent enhancer drives cell proliferation and liver tumorigenesis

Julie Sanceau,Lucie Poupel,Camille Joubel,Isabelle Lagoutte,Stefano Caruso,Sandra Pinto,Christèle Desbois-Mouthon,Cécile Godard,Akila Hamimi,Enzo Montmory,Cécile Dulary,Sophie Chantalat,Amélie Roehrig,Kevin Muret,Benjamin Saint-Pierre,Jean-François Deleuze,Sophie Mouillet-Richard,Thierry Forné,Christophe F Grosset,Jessica Zucman-Rossi,Sabine Colnot,Angélique Gougelet,Christophe F. Grosset
DOI: https://doi.org/10.1016/j.ymthe.2024.01.036
IF: 12.91
2024-02-01
Molecular Therapy
Abstract:The CTNNB1 gene, encoding β-catenin, is frequently mutated in hepatocellular carcinoma (HCC, ∼30%) and in hepatoblastoma (HB, &gt;80%), in which DLK1/DIO3 locus induction is correlated with CTNNB1 mutations. Here, we aim to decipher how sustained β-catenin activation regulates DLK1/DIO3 locus expression and the role this locus plays in HB and HCC development in mouse models deleted for Apc (Apc<sup>Δhep</sup>) or Ctnnb1-exon 3 (β-catenin<sup>ΔExon3</sup>) and in human CTNNB1-mutated hepatic cancer cells. We identified an enhancer site bound by TCF-4/β-catenin complexes in an open conformation upon sustained β-catenin activation (DLK1-Wnt responsive element [WRE]) and increasing DLK1/DIO3 locus transcription in β-catenin-mutated human HB and mouse models. DLK1-WRE editing by CRISPR-Cas9 approach impaired DLK1/DIO3 locus expression and slowed tumor growth in subcutaneous CTNNB1-mutated tumor cell grafts, Apc<sup>Δhep</sup> HB and β-catenin<sup>ΔExon3</sup> HCC. Tumor growth inhibition resulted either from increased FADD expression and subsequent caspase-3 cleavage in the first case or from decreased expression of cell cycle actors regulated by FoxM1 in the others. Therefore, the DLK1/DIO3 locus is an essential determinant of FoxM1-dependent cell proliferation during β-catenin-driven liver tumorigenesis. Targeting the DLK1-WRE enhancer to silence the DLK1/DIO3 locus might thus represent an interesting therapeutic strategy to restrict tumor growth in primary liver cancers with CTNNB1 mutations.
genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology
What problem does this paper attempt to address?